CD8A and breast cancer: Primary goal of our study was to evaluate the prognostic value of CD3, CD8, and FOXP3 mRNA expressions, as markers for T‐cell infiltration, in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy in the context of two prospective phase III randomized trials.